³ÁÔüÇÐƬ,deposit slicingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈýÔª¸´ºÏÒò×Ó,ternary complex factorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ѪÇå·´Ó¦Ôª¼þ,serum response elementÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½ºÔÑù·Ö×Ó,collagen-like moleculesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉÏÇ»¾²ÂöѹÆÈÕ÷,superior vena cava compression syndromeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÒÖÖÆÖ×ÁöÉú³¤,inhibition of tumor growthÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÆæÕýÏûÍ´Ìù,Qizhengxiaotong EmplastrumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×Ô·¢ÐÔÖ×Áö,spontaneous tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µ²Ç¦,lead-alloy blockÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Õæ¿Õ¸ºÑ¹´ü,vacuum bag with negative pressureÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸¹ÅèÇ»ÌåĤ,thermoplastic sheet for patients with abdominal or pelvic tumorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿¹Ö×Áö°Ðµã,anti-tumor targetÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖÎÁÆ´²,treatment couchÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼¡Çòµ°°×ÇáÁ´¼¤Ã¸/ÉúÀíѧ,Myosin-light-chain kinase/physiolÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µ¥ÌÇ·ÖÎö,monosaccharide analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶¯Ì¬ÊÊÐε÷Ç¿·ÅÁÆ,Four dimensional intensity modulated radiation therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
PDZµ°°×,PDZ proteinsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÖÎÁưеã,tumour therapeutic targetÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÄÍҩϸ°û,MDR CellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°û´¦Àí·½·¨,Cell Pretreatment MethodsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸¹Ë®Ï¸°ûѧ¼ì²é,ascetic cytological examinationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°×Ê×ÎÚ×ÜÜÕ,general steroidal glycosides from Radix Cynanchi AuriculatiÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¾«È··ÅÉäÖÎÁÆ,precise radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ͬÖÖºÍÒìÖÖѪ¹ÜÄÚƤϸ°û,Autologous and xenogeneic endothelial cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°×ÈýÏ©B4ÊÜÌå,Leukotriene B4 receptorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°©Ö¢ÖÎÓúÖ¸Êý,cancer cure indexÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×ÜÉ¢ÉäÒò×Ó,total scatter factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×¼Ö±Æ÷É¢ÉäÒò×Ó,collimator scatter factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×éÖ¯×î´ó¼ÁÁ¿±È,tissue-maximum ratioÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
СÕÕÉäÒ°,small fieldÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ñÐÔÖ×ÁöÏà¹ØÒò×Ó,Tumor-related factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´Å¹²ÕñÒýµ¼µÄ¸ßÇ¿¶È¾Û½¹³¬Éù,magnetic resonance imaging guided high intensity focused ultrasoundÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´Å¹²Õñ²âÎÂ,magnetic resonance imaging thermometryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁòËáÂð·È»ºÊÍƬ,morphine sulfate sustained-releease tabletsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½æËá»·¼ºõ¥,cyclohexyl erucateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿¹ÇÖÏ®»îÐÔ,Anti-invasive activityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
³ÉÈËÌÛÍ´,adult cancer painÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Èý½×ÌÝÕòÍ´,three-step analgesic laddersIÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Éñ¾²¡ÀíÐÔ°©Í´,neuropathic cancer painÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
תÒÆÐÔ¼¹ËèѹÆÈÖ¢,metastatic spinal cord compressionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÑϽ÷·ÖÎö,rigorous analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶þά¿ÕÆøµçÀëÊÒ¾ØÕó,2D air vented ionization chambers arrayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
SEZ6»ùÒò,SEZ6 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ʶ±ðÊÜÌå,recognition receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½ð±êÖ²Èë,gold implantationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÆøµÀ¶ñÐÔÏÁÕ,Malignant tracheal narrowÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÂÝ»·-ì¢Ëáõ¥À໯ºÏÎï,spiro-phosphonate derivateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Êý×Ö¼õÓ°¶¯ÂöÔìÓ°Êõ,Digital subtraction arteriography(DSA)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉÏƤÐÔÖ×Áöϸ°û,epithelial cancer cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Àà±ðת»»ÖØ×é,class switch recombinationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ïà¿ØÕóÈÈÁÆ,phased array hyperthermia treatmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Âå·Ò´ýÒòƬ,ibuprofen-codeine phosphate tabletsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°©Ï¸°ûתȾ,Cancer cell transferÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÔöÖ³Ðźŵ°°×,Proliferation of signalsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
MHC¢ñÀàÁ´Ïà¹Ø·Ö×ÓA/B,MHC¢ñ chain-related molecules A /BÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×éÖ¯²¹³¥,Organization CompensationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»ºÊÍÂð·È,sustained-release morphineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöѪ¹Ü°ÐÏòÖÎÁÆ,tumor vascular-targeted therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿¹Ñª¹ÜÐÂÉúÖƼÁ,antiangiogenic agentsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöѪ¹Ü×è¶ÏÖƼÁ,vascular-disrupting agentsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÈÈ,Tumor related feverÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
΢Âö¹Üϵͳ,Micro vasculatureÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¾Æ¤¸¹Ç»Éñ¾´Ô×èÖÍÊõ,Percutaneous neurolytic coelial plexus blockÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÚ¹²Éú½ø»¯,symbiogenetic evolutionaryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÎøËáÈí¹Ç¶àÌÇ,selenic acid cartilage polysaccharideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
DNAËðÉ˼ì²âµã·´Ó¦,DNA-damage checkpoint-responseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½ðÄÉÃ׿ÕÐÄÇò,hollow gold nano-particlesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÔØÌåÖØ°ÐÏò,vector retargetingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
²¡¶¾ÐÞÊÎ,virus modificationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ñ¡ÔñÐÔĤ,Selective filmÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ir/IrO_x-pHµç¼«,Ir/IrO_x-pH electrodeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÎÛȾ,PollutionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
³¬Éù²¨,ultrasonicÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÅÉäÁÆ·¨,RadiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÇÖÏ®,invasionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÅÁÆ,RadiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ìÊ,enthalpyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ã×ÍÐÝìõ«,mitoxantroneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÍØÆËÌ濵,TopotecanÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´Å¿Ø¹Ü,magnetronÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ñݽø,evolutionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÅÉäÍâ¿Æ,RadiosurgeryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÅÉäÃâÒßÏÔÏñ,radioimmunoimagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
±´·¥µ¥¿¹,bevacizumabÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö¬·¾ÈâÁö,LiposarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÚƤÒÖÖÆËØ,endostatinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿É´ýÒò,CodeineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»Ò¶È,GrayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áö/²¡Àíѧ,neoplasms/pathologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Á¦¶û·²,LifeinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Éú´æ,survivalÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
E-¸Æð¤ËØ,E-cadherinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Éñ¾õ£°·Àà,ceramidesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ѫ¹ÜÄÚƤÁö,hemangioendotheliomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ѫ¹ÜÉú³ÉÒÖÖÆËØ,AngiostatinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ý¼Ì,adoptiveÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö°©Îï,carcinogenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½âżÁª,uncouplingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÃâÒßżÁªÎï,immunoconjugateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸ß¼×»ù»¯,HypermethylationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
![](/css/logo.gif)
|